头孢吡肟
铜绿假单胞菌
微生物学
抗菌剂
杆菌
克
体外
革兰氏阴性菌
医学
生物
病毒学
抗生素耐药性
细菌
抗生素
亚胺培南
大肠杆菌
遗传学
生物化学
基因
作者
James A. Karlowsky,Meredith Hackel,Mark G. Wise,David A. Six,Tsuyoshi Uehara,Denis M. Daigle,Susan M Cusick,Daniel C. Pevear,Greg Moeck,Daniel F. Sahm
摘要
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n = 13,731) and Pseudomonas aeruginosa ( n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries.
科研通智能强力驱动
Strongly Powered by AbleSci AI